Amp kinase and malonyl-coa: Targets for therapy of the metabolic syndrome

@article{Ruderman2004AmpKA,
  title={Amp kinase and malonyl-coa: Targets for therapy of the metabolic syndrome},
  author={Neil Bertrand Ruderman and Marc Prentki},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={340-351}
}
Patients with the metabolic syndrome are characterized by insulin resistance, obesity and a predisposition to hypertension, dyslipidaemia, pancreatic β-cell dysfunction, type 2 diabetes and premature atherosclerosis. Here we review the hypothesis that a common feature linking these multiple abnormalities is dysregulation of the AMP-activated protein kinase (AMPK)/malonyl-CoA fuel-sensing and signalling network. It is proposed that such dysregulation leads to alterations in cellular fatty-acid… CONTINUE READING